With the rapid development of modern molecular biology techniques, more and more NSCLC driver mutations have been discovered, for example, epidermal growth factor receptor gene (EGFR), ananaplastic lymphoma kinase (ALK), rearrangements of the c-ros oncogene 1(ROS1), kirsten rat sarcoma viral oncogene homolog (KRAS), etc. Molecular genotyping has become critical in metastatic NSCLC, and the development of mutation-targeted therapies has revolutionized the treatment of NSCLC (11–14). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.